Amkor Technology R&D increased by 13.7% to $41.76M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 8.5%, from $45.65M to $41.76M. Over 4 years (FY 2021 to FY 2025), R&D shows relatively stable performance with a 0.1% CAGR.
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
research_and_development| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $43.52M | $40.79M | $37.41M | $38.36M | $37.48M | $33.99M | $39.59M | $47.05M | $45.69M | $43.14M | $41.60M | $38.17M | $39.57M | $42.36M | $42.85M | $45.65M | $42.01M | $42.35M | $36.73M | $41.76M |
| QoQ Change | — | -6.3% | -8.3% | +2.5% | -2.3% | -9.3% | +16.5% | +18.8% | -2.9% | -5.6% | -3.6% | -8.2% | +3.7% | +7.1% | +1.1% | +6.5% | -8.0% | +0.8% | -13.3% | +13.7% |
| YoY Change | — | — | — | — | -13.9% | -16.7% | +5.8% | +22.6% | +21.9% | +26.9% | +5.1% | -18.9% | -13.4% | -1.8% | +3.0% | +19.6% | +6.2% | -0.0% | -14.3% | -8.5% |
| Segment | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|
| Reportable Segment | $45.65M | $42.01M | $42.35M | $36.73M | $41.76M |
| Total | $45.65M | $42.01M | $42.35M | $36.73M | $41.76M |